High-Dose First-Line Treatment Regimen for Recurrent Rifampicin-Susceptible Tuberculosis.
作者信息
Decroo Tom, de Jong Bouke C, Piubello Alberto, Souleymane Mahamadou Bassirou, Lynen Lutgarde, Van Deun Armand
机构信息
Institute of Tropical MedicineAntwerp, Belgium.
Research Foundation FlandersBrussels, Belgium.
出版信息
Am J Respir Crit Care Med. 2020 Jun 15;201(12):1578-1579. doi: 10.1164/rccm.202001-0201LE.
Abstract
摘要
相似文献
1
High-Dose First-Line Treatment Regimen for Recurrent Rifampicin-Susceptible Tuberculosis.
Am J Respir Crit Care Med. 2020 Jun 15;201(12):1578-1579. doi: 10.1164/rccm.202001-0201LE.
2
Reply to Decroo : High-Dose First-Line Treatment Regimen for Recurrent Rifampicin-Susceptible Tuberculosis.
Am J Respir Crit Care Med. 2020 Jun 15;201(12):1579-1580. doi: 10.1164/rccm.202002-0359LE.
3
Treatment of isoniazid-resistant tuberculosis with isoniazid, rifampin, ethambutol, and pyrazinamide for 6 months.
Int J Tuberc Lung Dis. 2002 Nov;6(11):952-8.
4
Intermediate Susceptibility Dose-Dependent Breakpoints For High-Dose Rifampin, Isoniazid, and Pyrazinamide Treatment in Multidrug-Resistant Tuberculosis Programs.
Clin Infect Dis. 2018 Nov 13;67(11):1743-1749. doi: 10.1093/cid/ciy346.
5
Tuberculosis in neonates and infants: epidemiology, pathogenesis, clinical manifestations, diagnosis, and management issues.
Paediatr Drugs. 2005;7(4):219-34. doi: 10.2165/00148581-200507040-00002.
6
Occurrence of disputed rpoB mutations among Mycobacterium tuberculosis isolates phenotypically susceptible to rifampicin in a country with a low incidence of multidrug-resistant tuberculosis.
BMC Infect Dis. 2019 Jan 3;19(1):3. doi: 10.1186/s12879-018-3638-z.
7
Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis.
Lancet. 2015 May 2;385(9979):1738-1747. doi: 10.1016/S0140-6736(14)62002-X. Epub 2015 Mar 18.
8
Isoniazid resistance profile and associated levofloxacin and pyrazinamide resistance in rifampicin resistant and sensitive isolates/from pulmonary and extrapulmonary tuberculosis patients in Pakistan: A laboratory based surveillance study 2015-19.
PLoS One. 2020 Sep 23;15(9):e0239328. doi: 10.1371/journal.pone.0239328. eCollection 2020.
9
Treatment outcomes for isoniazid-monoresistant tuberculosis in Peru, 2012-2014.
PLoS One. 2018 Dec 4;13(12):e0206658. doi: 10.1371/journal.pone.0206658. eCollection 2018.
10
[Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
Kekkaku. 2003 Oct;78(10):611-7.
引用本文的文献
1
Quantitative measurement of antibiotic resistance in Mycobacterium tuberculosis reveals genetic determinants of resistance and susceptibility in a target gene approach.
Nat Commun. 2024 Jan 12;15(1):488. doi: 10.1038/s41467-023-44325-5.
2
Quantitative measurement of antibiotic resistance in reveals genetic determinants of resistance and susceptibility in a target gene approach.
Res Sq. 2023 Oct 2:rs.3.rs-3378915. doi: 10.21203/rs.3.rs-3378915/v1.
3
Genome-wide association studies of global Mycobacterium tuberculosis resistance to 13 antimicrobials in 10,228 genomes identify new resistance mechanisms.
PLoS Biol. 2022 Aug 9;20(8):e3001755. doi: 10.1371/journal.pbio.3001755. eCollection 2022 Aug.
4
A systematic review of endpoint definitions in late phase pulmonary tuberculosis therapeutic trials.
Trials. 2021 Aug 3;22(1):515. doi: 10.1186/s13063-021-05388-1.
5
Comparison of first-line tuberculosis treatment outcomes between previously treated and new patients: a retrospective study in Machakos subcounty, Kenya.
Int Health. 2021 Apr 27;13(3):272-280. doi: 10.1093/inthealth/ihaa051.
本文引用的文献
1
Early Bactericidal Activity of Different Isoniazid Doses for Drug-Resistant Tuberculosis (INHindsight): A Randomized, Open-Label Clinical Trial.
Am J Respir Crit Care Med. 2020 Jun 1;201(11):1416-1424. doi: 10.1164/rccm.201910-1960OC.
2
Principles for constructing a tuberculosis treatment regimen: the role and definition of core and companion drugs.
Int J Tuberc Lung Dis. 2018 Mar 1;22(3):239-245. doi: 10.5588/ijtld.17.0660.
3
High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.
Lancet Infect Dis. 2017 Jan;17(1):39-49. doi: 10.1016/S1473-3099(16)30274-2. Epub 2016 Oct 26.
4
Rifampin drug resistance tests for tuberculosis: challenging the gold standard.
J Clin Microbiol. 2013 Aug;51(8):2633-40. doi: 10.1128/JCM.00553-13. Epub 2013 Jun 12.
5
A randomised controlled trial of high-dose isoniazid adjuvant therapy for multidrug-resistant tuberculosis.
Int J Tuberc Lung Dis. 2008 Feb;12(2):139-45.
Zotero 插件